Company / Free Cash Flow per Share
Dianthus Therapeutics, Inc. /DE/ Free Cash Flow per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$2.50
FY2024
5-year range
-$33.41 / -$1.11
FY2020-FY2024
Trend
+65.2%
vs FY2023
Sector context
#144 of 192
Health Care
What the data says
Dianthus Therapeutics, Inc. /DE/'s free cash flow per share of $-2.50 is lower than 75% of companies in the Health Care sector (FY2024). Free Cash Flow per Share has fluctuated over the past 9 years, ranging from $-44.63 in FY2016 to $-1.11 in FY2021.
Based on SEC 10-K filings.
-2.50 in FY2024.
Improved from $-33.41 to $-2.50 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 192This company -$2.50 Sector average $3.32
▼
-175.2% below sector average
Key checks
Key Insights
- In FY2024, free cash flow per share increased 65.2% year-over-year.
- Ranks #144 out of 192 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2021.
- Lowest free cash flow per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -$2.50 | +65.2% |
| FY2023 | -$7.17 | +78.5% |
| FY2022 | -$33.41 | -2919.8% |
| FY2021 | -$1.11 | +24.6% |
| FY2020 | -$1.47 | +18.8% |
| FY2019 | -$1.81 | +91.4% |
| FY2018 | -$21.08 | -60.0% |
| FY2017 | -$13.17 | +70.5% |
| FY2016 | -$44.63 | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026